GABA-producing bacteria for improving health patent application

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published September 17th, 2025

Detected March 27th, 2026

Summary

The USPTO has published a new patent application (US20260083786A1) detailing a composition comprising Lactobacillus brevis (NCIMB 41903) for use in regulating or treating metabolic diseases. The application was filed on September 17, 2025, by inventors Paul Ross and Catherine Stanton.

View original document View source feed page

What changed

This document is a patent application (US20260083786A1) filed with the USPTO, disclosing a composition containing the isolated bacteria Lactobacillus brevis (NCIMB 41903). The application, filed on September 17, 2025, by inventors Paul Ross and Catherine Stanton, claims its use in a method for regulating or treating metabolic diseases or their symptoms.

As a patent application, this document does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future intellectual property and market exclusivity for specific therapeutic applications of this bacterial strain. Companies in the pharmaceutical and food manufacturing sectors should be aware of this filing as it may impact future product development and competitive landscapes in the area of metabolic health treatments.

Source document (simplified)

← USPTO Patent Applications

GABA-PRODUCING CULTURABLE BACTERIA AND USE FOR IMPROVING HEALTH

Application US20260083786A1 Kind: A1 Mar 26, 2026

Inventors

Paul Ross, Catherine Stanton

Abstract

A composition for use in a method of regulating or treating a metabolic disease or a symptom thereof, the composition comprising an isolated bacteria Lactobacillus brevis (DPC6108) deposited with the National Collection of Industrial and Marine Bacteria Limited (NCIMB) on 28 Nov. 2011 and accorded the accession number NCIMB 41903.